Research & Development
-
Nikida via Getty Images
Deep Dive‘The bar has risen’: China’s biotech gains push US companies to adapt
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder.
By Ben Fidler • Jan. 17, 2025 -
Anna Moneymaker via Getty Images
Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking
There’s more to pharma's regulatory story in 2025 than just the IRA.
By Meagan Parrish • Jan. 17, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Sundry Photography via Getty Images
Merck is broadening its pipeline as Keytruda’s patent cliff looms
Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.
By Alexandra Pecci • Jan. 14, 2025 -
iStock via Getty Images
Year in PreviewWill 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?
A series of uncertainties that kept dealmaking to a minimum last year could be reversing as pharma reloads pipelines ahead of the patent cliff explosion.
By Michael Gibney • Jan. 14, 2025 -
Sarah Silbiger via Getty Images
FDA ‘stuck to its corner’ with AI draft guidance, leaving plenty of questions unanswered
The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.
By Amy Baxter • Jan. 13, 2025 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
Coming changes that could impact pharma from drug development to launch.
By Meagan Parrish • Jan. 10, 2025 -
Permission granted by Candel Therapeutics
Q&A // Biotech SpotlightAfter layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.
By Michael Gibney • Jan. 9, 2025 -
Scott Olson via Getty Images
3 trial readouts that could shake up the obesity market this year
A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.
By Amy Baxter • Jan. 8, 2025 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: The industry’s AI future
How AI will further transform the business of drug discovery and development in 2025.
By Meagan Parrish • Jan. 7, 2025 -
iStock via Getty Images
Subcutaneous options offer convenience for patients — and a valuable window for drugmakers
New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.
By Kelly Bilodeau • Jan. 7, 2025 -
Stock via Getty Images
4 closely watched FDA approval dates in 2025 from J&J, Novo and more
A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.
By Alexandra Pecci • Jan. 6, 2025 -
Stock via Getty Images
4 companies to watch in the accelerating gene editing race
A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.
By Kelly Bilodeau • Jan. 2, 2025 -
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
Sundry Photography via Getty Images
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market
A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.
By Michael Gibney • Dec. 19, 2024 -
PeopleImages via Getty Images
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.
By Michael Gibney • Dec. 17, 2024 -
Stock via Getty Images
A biotech’s race to tackle the most severe hepatitis
Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.
By Alexandra Pecci • Dec. 17, 2024 -
Courtesy of Roche
3 closely watched drugs that failed in the clinic
How recent setbacks and scattered successes could impact various sectors of the industry.
By Kelly Bilodeau • Dec. 16, 2024 -
Stock via Getty Images
Oncology, obesity and more: Where pharma R&D is headed in 2025
With a little more certainty coming to the market, the R&D environment in 2025 will be about pipeline prioritization and accelerating M&A.
By Amy Baxter • Dec. 16, 2024 -
Stock via Getty Images
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
By Meagan Parrish • Dec. 13, 2024 -
Permission granted by Regeneron
Q&ARegeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.
By Michael Gibney • Dec. 12, 2024 -
Pony Wang via Getty Images
Deep DiveEndometriosis drug research, long underfunded, confronts familiar problems in women’s health
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By Delilah Alvarado • Dec. 11, 2024 -
Justin Sullivan via Getty Images
What’s next for 23andMe?
Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.
By Alexandra Pecci • Dec. 10, 2024 -
Magdalena Wygralak via Getty Images
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could change the tide.
By Michael Gibney • Dec. 10, 2024 -
Stock via Getty Images
Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide
Leading companies in the psychedelics space have had trouble crossing the regulatory threshold. Here’s where they’re going wrong — and how to fix it.
By Kelly Bilodeau • Dec. 9, 2024 -
Permission granted by Astellas
Q&AHow Astellas juggles the moving parts of cancer precision medicine development
While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.
By Michael Gibney • Dec. 5, 2024
